Manol Jovani1,2, Wenjie Ma1,2, Amit D Joshi1,2, Po-Hong Liu1,2, Long H Nguyen1,2, Yin Cao1,2,3, Idy Tam4, Kana Wu5, Edward L Giovannucci5,6, Andrew T Chan1,2,6,7, Lisa L Strate8. 1. Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. 2. Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 3. Division of Public Health Sciences, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA. 4. Tufts University School of Medicine, Boston, Massachusetts, USA. 5. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. 6. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 7. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. 8. Division of Gastroenterology, University of Washington School of Medicine, Seattle, Washington, USA.
Abstract
INTRODUCTION: Diverticulitis is a significant cause of morbidity among older women, and little attention has been paid to understanding its etiology. We have shown that menopausal hormone therapy (MHT) is associated with the risk of inflammatory bowel disease. In this study, we prospectively examined the association between MHT and the risk of incident diverticulitis. METHODS: We studied 65,367 postmenopausal women enrolled in the Nurses' Health Study who provided detailed information on hormone use and other medical and lifestyle factors biennially, and on diet every 4 years. Between 2008 and 2014, participants reported any episodes of diverticulitis that required antibiotics and the date of occurrence. We used Cox proportional hazards regression models to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Over 24 years encompassing 1,297,165 person-years of follow-up, we documented 5,425 incident cases of diverticulitis. We observed an increased risk of diverticulitis among both current (HR 1.28; 95% CI 1.18-1.39) and past (HR 1.35; 95% CI 1.25-1.45) MHT users compared to never users. The increased risk was observed among participants using estrogen only (HR 1.30; 95% CI 1.20-1.41) and those using combined estrogen and progesterone (HR 1.31; 95% CI 1.21-1.42) compared to nonusers. The risk did not increase with longer duration of use (P-trend = 0.76). The association between MHT and diverticulitis was not modified by age, body mass index, past oral contraceptive use, or fiber intake (all P-interaction >0.11). CONCLUSIONS: Menopausal hormone therapy was associated with an increased risk of diverticulitis. Further studies are needed to understand the potential mechanisms that may underlie this association.
INTRODUCTION:Diverticulitis is a significant cause of morbidity among older women, and little attention has been paid to understanding its etiology. We have shown that menopausal hormone therapy (MHT) is associated with the risk of inflammatory bowel disease. In this study, we prospectively examined the association between MHT and the risk of incident diverticulitis. METHODS: We studied 65,367 postmenopausal women enrolled in the Nurses' Health Study who provided detailed information on hormone use and other medical and lifestyle factors biennially, and on diet every 4 years. Between 2008 and 2014, participants reported any episodes of diverticulitis that required antibiotics and the date of occurrence. We used Cox proportional hazards regression models to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Over 24 years encompassing 1,297,165 person-years of follow-up, we documented 5,425 incident cases of diverticulitis. We observed an increased risk of diverticulitis among both current (HR 1.28; 95% CI 1.18-1.39) and past (HR 1.35; 95% CI 1.25-1.45) MHT users compared to never users. The increased risk was observed among participants using estrogen only (HR 1.30; 95% CI 1.20-1.41) and those using combined estrogen and progesterone (HR 1.31; 95% CI 1.21-1.42) compared to nonusers. The risk did not increase with longer duration of use (P-trend = 0.76). The association between MHT and diverticulitis was not modified by age, body mass index, past oral contraceptive use, or fiber intake (all P-interaction >0.11). CONCLUSIONS: Menopausal hormone therapy was associated with an increased risk of diverticulitis. Further studies are needed to understand the potential mechanisms that may underlie this association.
Authors: Lisa L Strate; Brieze R Keeley; Yin Cao; Kana Wu; Edward L Giovannucci; Andrew T Chan Journal: Gastroenterology Date: 2017-01-05 Impact factor: 22.682
Authors: Stephanie E Chiuve; Teresa T Fung; Eric B Rimm; Frank B Hu; Marjorie L McCullough; Molin Wang; Meir J Stampfer; Walter C Willett Journal: J Nutr Date: 2012-04-18 Impact factor: 4.798
Authors: Miguel Gueimonde; Arthur Ouwehand; Heikki Huhtinen; Eeva Salminen; Seppo Salminen Journal: World J Gastroenterol Date: 2007-08-07 Impact factor: 5.742
Authors: Anne F Peery; Alexander Keil; Katherine Jicha; Joseph A Galanko; Robert S Sandler Journal: Clin Gastroenterol Hepatol Date: 2019-05-08 Impact factor: 11.382
Authors: Wenjie Ma; Long H Nguyen; Mingyang Song; Manol Jovani; Po-Hong Liu; Yin Cao; Idy Tam; Kana Wu; Edward L Giovannucci; Lisa L Strate; Andrew T Chan Journal: Am J Gastroenterol Date: 2019-09 Impact factor: 10.864
Authors: Manol Jovani; Wenjie Ma; Kyle Staller; Amit D Joshi; Po-Hong Liu; Long H Nguyen; Paul Lochhead; Yin Cao; Idy Tam; Kana Wu; Edward L Giovannucci; Lisa L Strate; Andrew T Chan Journal: Clin Gastroenterol Hepatol Date: 2021-01-05 Impact factor: 11.382
Authors: Mahmut Kaan Demircioglu; Zeynep Gul Demircioglu; Mustafa Fevzi Celayir; Cemal Kaya; Mehmet Mihmanli Journal: Sisli Etfal Hastan Tip Bul Date: 2020-12-11